Find a Pharmacy
Vertice Login
Info banner
A significant part of the Healthesystems vision is to create a more integrated experience for our customers

What's Happening

Stay up to date on conferences, social posts, and what’s new with Healthesystems

Events

Let’s connect at one of our upcoming conferences or speaking engagements

MedMonitor

An up-to-date timeline of FDA approvals that could impact workers' comp
View All MedMonitor Information

Idacio® (adalimumab-aacf) injection

Approval Date: Dec 2022

Note: New Product

Indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, and plaque psoriasis

hello world!

Tzield® (teplizumab-mzwv) injection

Approval Date: Nov 2022

Note: New Product

A first-in-class medication, this drug is indicated to delay the onset of Stage 3 type 1 diabetes, potentially delaying the clinical diagnosis of type 1 diabetes to provide patients with months to years without the burdens of disease.

hello world!

Daliresp® (roflumilast) tablets

Approval Date: Sep 2022

Note: First-Time Generic

Indicated to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations

hello world!

Tazorac® (tazarotene) gel

Approval Date: Sep 2022

Note: First-Time Generic

Indicated for the topical treatment of plaque psoriasis of up to 20% body surface area involvement

hello world!

Byvalson (nebivolol and valsartan) tablets

Approval Date: Sep 2022

Note: First-Time Generic

Indicated for the treatment of hypertension, to lower blood pressure

hello world!

Prezista® (darunavir) tablets

Approval Date: Sep 2022

Note: First-Time Generic

Indicated for the treatment of HIV-1 infection

hello world!

Sotyktu (deucravacitnib) tablets

Approval Date: Sep 2022

Note: New Product

Indicated for the treatment of moderate-to-severe plaque psoriasis in patients who are candidates for systemic therapy or phototherapy

hello world!

Jardiance® (empagliflozin) tablets

Approval Date: Aug 2022

Note: First-Time Generic

Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes

hello world!

Rexulti® (brexpiprazole) tablets

Approval Date: Aug 2022

Note: First-Time Generic

Indicated for the adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD)

hello world!

Banzel® (rufinamide) tablets

Approval Date: Aug 2022

Note: First-Time Generic

Indicated for the adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome

hello world!

Auvelity (dextromethorphan hydrobromide and bupropion hydrochloride) extended-release tablets

Approval Date: Aug 2022

Note: New Product

For the treatment of major depressive disorder, this antidepressant is notable for producing antidepressant results within one week

hello world!

Synjardy® (empagliflozin and metformin hydrochloride) tablets

Approval Date: Jul 2022

Note: First-Time Generic

Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes

hello world!

Edarbi® (azilsartan medoxomil) tablets

Approval Date: Jul 2022

Note: First-Time Generic

Indicated for the treatment of hypertension to lower blood pressure

hello world!

Nalfon® (fenoprofen calcium) tablets

Approval Date: Jul 2022

Note: First-Time Generic

An NSAID used for the relief of mild to moderate pain or relief in the signs and symptoms of rheumatoid arthritis or osteoarthritis

hello world!

Zoryve (roflumilast) cream

Approval Date: Jul 2022

Note: New Product

Indicated for topical treatment of plaque psoriasis

hello world!
1 4 5 6 7 8 10

Social Hub

Check out our latest posts and activity
View All Social Media
    lockmap-markermagnifiercrossmenucross-circle